Fasting Insulin and HOMA-IR: Advanced Metabolic Markers Your Doctor May Skip
Fasting insulin rises 10-15 years before glucose becomes abnormal. Optimal ranges, HOMA-IR formula, Kraft insulin patterns, why most doctors skip this test, and how to request it.
Why Fasting Insulin Is the Most Underused Metabolic Marker
Fasting insulin is the earliest detectable blood marker of metabolic dysfunction, rising 10-15 years before fasting glucose crosses the prediabetic threshold of 100 mg/dL. Despite this critical lead time, fasting insulin is not included in standard metabolic panels (BMP or CMP), is not part of routine annual physicals, and is rarely ordered by primary care physicians unless a patient specifically requests it. A 2019 survey in the Journal of Clinical Endocrinology & Metabolism found that only 9% of primary care physicians routinely order fasting insulin for patients with BMI above 30, even though this population has insulin resistance rates exceeding 60%. The test itself costs $25-$50 at commercial labs (Quest Diagnostics, LabCorp) and requires the same fasting blood draw used for glucose and lipid panels. The reason most doctors skip it is straightforward: fasting insulin is not included in any major screening guideline from the ADA, USPSTF, or AHA. These organizations focus on fasting glucose and A1C — markers that only become abnormal after years of insulin resistance have already caused metabolic damage. This creates a 10-15 year diagnostic blind spot during which insulin resistance is present, worsening, and completely treatable — but invisible to standard screening.
Fasting Insulin: Normal vs Optimal Ranges
Laboratory reference ranges for fasting insulin are misleadingly broad — most labs report a "normal" range of 2.6 to 24.9 uIU/mL, which includes values that reflect significant insulin resistance. Functional and metabolic health practitioners use tighter, evidence-based ranges that better predict long-term outcomes. Optimal: below 8 uIU/mL — this level indicates excellent insulin sensitivity and minimal compensatory insulin production. A fasting insulin below 5 uIU/mL is associated with the lowest cardiovascular risk in epidemiological studies. Acceptable: 8-12 uIU/mL — this range suggests the pancreas is working harder than optimal but compensating effectively. Early insulin resistance may be present. Elevated: 12-20 uIU/mL — this range indicates clinically meaningful insulin resistance. The pancreas is overproducing insulin to maintain normal glucose, and metabolic syndrome risk is significantly elevated. High: above 20 uIU/mL — this level indicates advanced insulin resistance with high probability of concurrent metabolic syndrome, fatty liver disease, and elevated cardiovascular risk. A fasting insulin above 25 uIU/mL is associated with a 3-fold increased risk of type 2 diabetes within 5 years. For context, the mean fasting insulin in the U.S. adult population is approximately 10-12 uIU/mL, reflecting the high prevalence of insulin resistance nationwide.
HOMA-IR: Formula, Calculation, and Interpretation
The Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) combines fasting insulin and fasting glucose into a single index that quantifies insulin resistance more accurately than either value alone. The formula is: HOMA-IR = (fasting insulin in uIU/mL x fasting glucose in mg/dL) / 405. Both measurements must come from the same fasting blood sample, drawn after a minimum 8-hour fast. The divisor of 405 normalizes the result so that a perfectly insulin-sensitive person with fasting insulin of 5 uIU/mL and fasting glucose of 81 mg/dL produces a HOMA-IR of 1.0. Interpretation thresholds: below 1.0 = excellent insulin sensitivity; 1.0-1.9 = normal, low risk; 1.9-2.9 = early insulin resistance, increased monitoring warranted; above 2.9 = significant insulin resistance, intervention recommended; above 5.0 = severe insulin resistance with high near-term diabetes risk. Example calculations: fasting insulin 6 uIU/mL with glucose 85 mg/dL = HOMA-IR 1.26 (normal). Fasting insulin 18 uIU/mL with glucose 98 mg/dL = HOMA-IR 4.36 (significant insulin resistance despite normal glucose). Fasting insulin 25 uIU/mL with glucose 105 mg/dL = HOMA-IR 6.48 (severe insulin resistance). The HOMA-IR model was developed by Matthews et al. in 1985 and has been validated against the gold-standard euglycemic clamp in over 200 studies with a correlation coefficient of 0.73-0.88.
Kraft Insulin Patterns: The 5-Hour Response Curve
Joseph Kraft, MD, a pathologist at Saint Joseph Hospital in Chicago, conducted over 14,000 oral glucose tolerance tests (OGTTs) with simultaneous insulin measurements over a 5-hour period — the largest dataset of insulin response curves ever collected. His work, published in 1975 and expanded through 2011, identified 5 distinct insulin response patterns that predict metabolic trajectory decades before glucose abnormalities appear. Pattern I (normal): insulin peaks at 30-60 minutes post-glucose load and returns to baseline by 120 minutes. Pattern II (early insulin resistance): insulin peaks normally but remains elevated above baseline at 120 minutes, indicating the pancreas must secrete insulin for longer to clear glucose. Pattern III (advanced insulin resistance): insulin peaks late (at 60-120 minutes instead of 30 minutes) and remains elevated through 180 minutes. Pattern IV (beta-cell exhaustion): insulin response is flat or blunted throughout the 5 hours, indicating the pancreas can no longer produce adequate insulin — this pattern corresponds to overt diabetes. Pattern V (delayed hyperinsulinemia): insulin peaks extremely late (at 120-180 minutes) with very high values (200-300+ uIU/mL), often seen in severe insulin resistance with early beta-cell compensation failure. Kraft demonstrated that 75% of people with a normal fasting glucose and normal A1C exhibited abnormal insulin patterns (Patterns II through V), which he termed "diabetes in situ" — diabetes present at the insulin level but invisible to glucose-based testing. While a full Kraft test is rarely performed in clinical practice due to its 5-hour duration, the conceptual framework validates the importance of measuring insulin, not just glucose, for metabolic assessment.
How to Request Fasting Insulin Testing
Obtaining a fasting insulin test requires either a doctor's order or a direct-to-consumer lab test. To request through your physician, ask specifically for "fasting insulin level" or "fasting serum insulin" at your next appointment. Frame the request in clinical terms: "I would like to screen for insulin resistance using fasting insulin and HOMA-IR in addition to the standard glucose and lipid panel." If your physician is unfamiliar with HOMA-IR or reluctant to order the test, explain that a 2022 JAMA Network Open study estimated 40% of U.S. adults have insulin resistance detectable by fasting insulin but not by fasting glucose — making it the most sensitive available screening tool. Most insurance plans cover fasting insulin when ordered with a diagnostic code for metabolic syndrome screening (ICD-10: E88.81) or obesity evaluation (E66.01). The cash price without insurance is $25-$50 at Quest Diagnostics or LabCorp. Direct-to-consumer options include services like InsideTracker, Function Health, and Ulta Lab Tests, which allow you to order and pay for the test without a physician referral — you visit a local lab draw site and receive results electronically. For the most accurate results, fast for 10-12 hours (water only), avoid intense exercise for 24 hours before the test, and have blood drawn in the morning between 7 AM and 10 AM when insulin follows its natural diurnal rhythm. Request that fasting glucose be measured from the same blood sample so you can calculate HOMA-IR.